Noramco
Noramco
Noramco
  • About Us
    • About Noramco
    • Our People
    • Leadership
    • Excellence in Compliance
    • Minimizing Risk
  • Products & Solutions
    • Active Pharmaceutical Ingredients
      • Active Pharmaceutical Ingredients
      • Nal Family of Antagonists
      • ADHD / Stimulants
      • Full Product List
    • Noramco Solutions
      • Noramco Solutions
      • Clinical Supply
      • Controlled Substance Building Blocks and Intermediates
    • Platform Technologies
      • Platform Technologies
      • Platform Technology: Custom Synthesis
    • Reference Standards
      • Reference Standards
      • Reference Standards: Custom Synthesis
    • Reference Standards Store
  • Careers
  • News & Events
    • News & Events
    • Press Releases
  • Contact

Sort by

  • Default sorting
  • Sort by popularity
  • Sort by newness
  • Sort by price: low to high
  • Sort by price: high to low

View

  • 9 items
  • 15 items
  • 30 items

Showing 1–9 of 10 results

  • 111_10-Ketomorphine
    Quick ViewRead more

    10-Ketomorphine (CII)

    <span style="color: #000000;"><strong>CAS#</strong></span> 68254-48-8 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-1093-**
    Quick ViewRead more
  • 112_10-Hydroxymorphine
    Quick ViewRead more

    10-Hydroxymorphine (CII)

    <span style="color: #000000;"><strong>CAS#</strong></span> 131563-73-0 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-0939-**
    Quick ViewRead more
  • 87_Morphine-Sulfate
    Quick ViewSelect options

    Morphine Sulfate (CII)

    $58.00 – $290.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 64-31-3 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-0017-**
    Quick ViewSelect options
  • 61_Codeine-Base
    Quick ViewSelect options

    Codeine Base (CII)

    $232.00 – $1,160.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 76-57-3 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-0009-**
    Quick ViewSelect options
  • 113_14-hydroxymorphine-Base
    Quick ViewSelect options

    14-hydroxymorphine Base (CII)

    $288.00 – $1,152.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 3371-56-0 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-1088-**
    Quick ViewSelect options
  • 119_Oripavine-Base
    Quick ViewSelect options

    Oripavine Base (CII)

    $288.00 – $1,152.00
    <span style="color: #000000;"><strong>OTHER NAMES:</strong></span> EP Impurity C <span style="color: #000000;"><strong>CAS#</strong></span> 467-04-9 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-0001-**
    Quick ViewSelect options
  • 65_Morphine-Base
    Quick ViewSelect options

    Morphine Base (CII)

    $575.00 – $2,875.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 57-27-2 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-0018-**
    Quick ViewSelect options
  • 116_Morphine-N-Oxide
    Quick ViewSelect options

    Morphine N-Oxide (CI)

    $719.00 – $2,876.00
    <span style="color: #000000;"><strong>OTHER NAMES:</strong></span> USP Compound A; EP Impurity F <span style="color: #000000;"><strong>CAS#</strong></span> 639-46-3 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-0907-**
    Quick ViewSelect options
  • 120_Pseudomorphine-Base
    Quick ViewSelect options

    Pseudomorphine Base (CII)

    $719.00 – $2,876.00
    <span style="color: #000000;"><strong>OTHER NAMES:</strong></span> USP Compound B; EP Impurity B 2,2'-bimorphine <span style="color: #000000;"><strong>CAS#</strong></span> 125-24-6 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-0902-**
    Quick ViewSelect options
  • 1
  • 2

Recent Articles

  • Noramco CEO Lee Karras discusses $25 million Halo investment with PharmTech
  • Diversifying the Supply of Raw Materials
  • Noramco Announces Strategic Alignment with Purisys and Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API and Drug Product Supply Chain Services Provider
  • Noramco Announces the Acquisition of the Cambrex Drug Product Business Unit
  • Noramco Announces Submission and Reactivation of the Drug Master File for Active Pharmaceutical Ingredient Methylnaltrexone Bromide
Copyright 2025 Noramco. All Rights Reserved. Contact | Legal Notice | Privacy Policy | Terms & Conditions | Benefits Transparency Mandate